Blood cancer transplant trial using banked donor marrow pulled before start
NCT ID NCT05170828
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial aimed to test whether bone marrow from deceased, mismatched unrelated donors could be safely used for transplants in patients with blood cancers like leukemia. The approach used stored (cryopreserved) marrow along with drugs to prevent rejection. However, the study was withdrawn before any participants were enrolled, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cryopreserved bone marrow from deceased mismatched unrelated donors
- What this could lead to
- If successful, this approach could expand donor options for blood cancer patients who need a bone marrow transplant but lack a perfect match.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results exist. The approach is early-stage (Phase 1) and carries risks like graft failure, infection, and graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE BIPHENOTYPIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?